 Rohit Katial
Concepts (429)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 59 | 2025 | 1768 | 6.750 |
Why?
| | Anti-Asthmatic Agents | 26 | 2025 | 252 | 5.130 |
Why?
| | Hypersensitivity | 9 | 2024 | 252 | 2.740 |
Why?
| | Biological Products | 13 | 2025 | 252 | 2.710 |
Why?
| | Aspirin | 11 | 2018 | 400 | 2.480 |
Why?
| | Respiratory Tract Diseases | 6 | 2016 | 175 | 2.120 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2018 | 20 | 2.080 |
Why?
| | Rhinitis, Allergic, Seasonal | 8 | 2012 | 25 | 2.050 |
Why?
| | Sinusitis | 11 | 2024 | 229 | 2.000 |
Why?
| | Adrenal Cortex Hormones | 16 | 2025 | 479 | 1.680 |
Why?
| | Rhinitis | 7 | 2024 | 171 | 1.500 |
Why?
| | Eosinophils | 17 | 2025 | 316 | 1.440 |
Why?
| | Nitric Oxide | 8 | 2024 | 897 | 1.340 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 7 | 2018 | 338 | 1.310 |
Why?
| | Nasal Polyps | 7 | 2024 | 59 | 1.260 |
Why?
| | Eosinophilic Esophagitis | 2 | 2024 | 330 | 1.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 16 | 2024 | 988 | 1.220 |
Why?
| | Rhinitis, Allergic | 4 | 2024 | 42 | 1.210 |
Why?
| | Allergens | 7 | 2024 | 384 | 1.140 |
Why?
| | Immunoglobulin E | 7 | 2025 | 315 | 1.130 |
Why?
| | Eosinophilia | 7 | 2024 | 221 | 1.120 |
Why?
| | Skin Tests | 3 | 2024 | 94 | 1.080 |
Why?
| | Histamine Antagonists | 4 | 2011 | 20 | 1.060 |
Why?
| | Mast Cells | 3 | 2023 | 146 | 1.000 |
Why?
| | Cost of Illness | 3 | 2024 | 321 | 0.970 |
Why?
| | Exhalation | 2 | 2018 | 29 | 0.930 |
Why?
| | Anti-Allergic Agents | 4 | 2018 | 40 | 0.930 |
Why?
| | Desensitization, Immunologic | 4 | 2016 | 89 | 0.930 |
Why?
| | Immunologic Deficiency Syndromes | 3 | 2016 | 65 | 0.850 |
Why?
| | Humans | 116 | 2025 | 144957 | 0.840 |
Why?
| | Angioedema | 1 | 2024 | 15 | 0.830 |
Why?
| | Severity of Illness Index | 14 | 2025 | 2925 | 0.810 |
Why?
| | Immunotherapy | 5 | 2017 | 657 | 0.810 |
Why?
| | Urticaria | 1 | 2024 | 38 | 0.810 |
Why?
| | Mastocytosis | 1 | 2023 | 11 | 0.810 |
Why?
| | Proton Pump Inhibitors | 1 | 2024 | 109 | 0.790 |
Why?
| | Remission Induction | 6 | 2025 | 308 | 0.780 |
Why?
| | Gastritis | 1 | 2024 | 115 | 0.760 |
Why?
| | Enteritis | 1 | 2024 | 103 | 0.750 |
Why?
| | Deglutition Disorders | 1 | 2024 | 147 | 0.750 |
Why?
| | Biomarkers | 10 | 2025 | 4275 | 0.730 |
Why?
| | Allergy and Immunology | 2 | 2024 | 42 | 0.680 |
Why?
| | Albuterol | 3 | 2010 | 73 | 0.670 |
Why?
| | Pancreatitis | 2 | 2012 | 145 | 0.670 |
Why?
| | Androstadienes | 2 | 2010 | 76 | 0.630 |
Why?
| | Breath Tests | 4 | 2007 | 79 | 0.630 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 489 | 0.620 |
Why?
| | Sputum | 4 | 2024 | 308 | 0.610 |
Why?
| | Drug Hypersensitivity | 4 | 2016 | 90 | 0.570 |
Why?
| | Antibodies, Monoclonal | 4 | 2025 | 1524 | 0.560 |
Why?
| | Bronchial Provocation Tests | 3 | 2018 | 47 | 0.550 |
Why?
| | Biological Therapy | 1 | 2017 | 28 | 0.500 |
Why?
| | Adult | 46 | 2025 | 40506 | 0.490 |
Why?
| | STAT6 Transcription Factor | 1 | 2016 | 24 | 0.480 |
Why?
| | Insect Bites and Stings | 1 | 2016 | 13 | 0.470 |
Why?
| | Middle Aged | 36 | 2025 | 35928 | 0.440 |
Why?
| | Administration, Intranasal | 6 | 2011 | 93 | 0.440 |
Why?
| | Vaccination | 3 | 2012 | 1423 | 0.430 |
Why?
| | Practice Guidelines as Topic | 7 | 2024 | 1563 | 0.430 |
Why?
| | Anaphylaxis | 1 | 2016 | 102 | 0.430 |
Why?
| | Double-Blind Method | 10 | 2025 | 2029 | 0.410 |
Why?
| | Forced Expiratory Volume | 3 | 2018 | 449 | 0.390 |
Why?
| | Male | 44 | 2025 | 72406 | 0.370 |
Why?
| | Treatment Outcome | 20 | 2025 | 11695 | 0.370 |
Why?
| | Female | 46 | 2025 | 78376 | 0.370 |
Why?
| | Bronchial Hyperreactivity | 3 | 2018 | 96 | 0.360 |
Why?
| | T-Lymphocyte Subsets | 2 | 2009 | 415 | 0.350 |
Why?
| | Chronic Disease | 9 | 2024 | 1813 | 0.340 |
Why?
| | Young Adult | 14 | 2025 | 14126 | 0.330 |
Why?
| | Disease Progression | 5 | 2023 | 2852 | 0.330 |
Why?
| | Pulmonary Eosinophilia | 2 | 2022 | 26 | 0.320 |
Why?
| | Dermatitis, Atopic | 2 | 2024 | 321 | 0.320 |
Why?
| | Aged | 15 | 2025 | 25947 | 0.310 |
Why?
| | Acetates | 1 | 2010 | 80 | 0.300 |
Why?
| | Vaccines | 2 | 2004 | 389 | 0.290 |
Why?
| | Adolescent | 15 | 2025 | 22453 | 0.280 |
Why?
| | Nose | 1 | 2009 | 68 | 0.280 |
Why?
| | Quinolines | 1 | 2010 | 193 | 0.280 |
Why?
| | Laryngismus | 1 | 2008 | 10 | 0.270 |
Why?
| | Leukotriene E4 | 1 | 2008 | 24 | 0.270 |
Why?
| | Vocal Cords | 1 | 2008 | 26 | 0.270 |
Why?
| | Immunity, Cellular | 2 | 2007 | 272 | 0.270 |
Why?
| | United States | 7 | 2024 | 15988 | 0.270 |
Why?
| | Diagnosis, Differential | 5 | 2017 | 1495 | 0.260 |
Why?
| | Food Hypersensitivity | 2 | 2009 | 164 | 0.250 |
Why?
| | Gastrointestinal Diseases | 1 | 2009 | 216 | 0.250 |
Why?
| | Paranasal Sinuses | 2 | 2020 | 81 | 0.240 |
Why?
| | Quality of Life | 6 | 2025 | 3192 | 0.240 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2009 | 389 | 0.230 |
Why?
| | Ethyl Chloride | 1 | 2005 | 1 | 0.230 |
Why?
| | Matrix Metalloproteinase 9 | 3 | 2011 | 132 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2004 | 398 | 0.230 |
Why?
| | Mastocytosis, Systemic | 1 | 2005 | 7 | 0.230 |
Why?
| | Biosimilar Pharmaceuticals | 1 | 2025 | 28 | 0.220 |
Why?
| | Nebulizers and Vaporizers | 3 | 2015 | 62 | 0.220 |
Why?
| | Conjunctivitis, Allergic | 1 | 2004 | 4 | 0.220 |
Why?
| | Alternaria | 2 | 2002 | 9 | 0.220 |
Why?
| | Immunoglobulin G | 2 | 2025 | 893 | 0.220 |
Why?
| | Heartburn | 1 | 2024 | 12 | 0.220 |
Why?
| | Cytokines | 3 | 2016 | 2065 | 0.210 |
Why?
| | Anesthetics, Local | 1 | 2005 | 100 | 0.210 |
Why?
| | Gastroesophageal Reflux | 2 | 2024 | 236 | 0.210 |
Why?
| | Analgesia | 1 | 2005 | 105 | 0.210 |
Why?
| | Syphilis | 1 | 2004 | 33 | 0.210 |
Why?
| | Serum Sickness | 1 | 2004 | 4 | 0.210 |
Why?
| | Antigens, Bacterial | 2 | 2002 | 127 | 0.210 |
Why?
| | Exanthema | 1 | 2004 | 84 | 0.210 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2004 | 81 | 0.210 |
Why?
| | Bioterrorism | 1 | 2004 | 31 | 0.210 |
Why?
| | Administration, Inhalation | 3 | 2016 | 575 | 0.210 |
Why?
| | Bupropion | 1 | 2004 | 47 | 0.200 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2004 | 59 | 0.200 |
Why?
| | Child | 10 | 2025 | 22657 | 0.200 |
Why?
| | Cockroaches | 1 | 2003 | 22 | 0.200 |
Why?
| | Registries | 7 | 2025 | 2385 | 0.200 |
Why?
| | Geography | 1 | 2024 | 203 | 0.200 |
Why?
| | Consensus | 1 | 2025 | 489 | 0.190 |
Why?
| | Research Design | 1 | 2009 | 1137 | 0.190 |
Why?
| | Glycoproteins | 2 | 2002 | 355 | 0.190 |
Why?
| | Signal Transduction | 2 | 2016 | 5233 | 0.190 |
Why?
| | Recurrence | 2 | 2017 | 1135 | 0.190 |
Why?
| | Lolium | 1 | 2002 | 2 | 0.190 |
Why?
| | Age of Onset | 1 | 2024 | 551 | 0.180 |
Why?
| | Poaceae | 1 | 2002 | 61 | 0.180 |
Why?
| | Neisseria meningitidis | 1 | 2002 | 23 | 0.180 |
Why?
| | Interferon-gamma | 3 | 2016 | 784 | 0.180 |
Why?
| | Pulmonary Atelectasis | 1 | 2002 | 16 | 0.180 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2022 | 117 | 0.180 |
Why?
| | Polysaccharides, Bacterial | 1 | 2002 | 67 | 0.170 |
Why?
| | Meningococcal Vaccines | 1 | 2002 | 58 | 0.170 |
Why?
| | Vaccines, Synthetic | 1 | 2002 | 138 | 0.170 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 28 | 0.170 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2002 | 61 | 0.170 |
Why?
| | Clinical Trials as Topic | 4 | 2011 | 1054 | 0.170 |
Why?
| | Tuberculin | 1 | 2001 | 8 | 0.170 |
Why?
| | Hypersensitivity, Delayed | 1 | 2001 | 29 | 0.170 |
Why?
| | Tuberculin Test | 1 | 2001 | 36 | 0.170 |
Why?
| | Bronchodilator Agents | 1 | 2022 | 183 | 0.170 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2025 | 365 | 0.160 |
Why?
| | Fluticasone-Salmeterol Drug Combination | 2 | 2010 | 7 | 0.160 |
Why?
| | Reference Values | 4 | 2007 | 798 | 0.160 |
Why?
| | Tuberculosis, Pulmonary | 1 | 2001 | 131 | 0.150 |
Why?
| | Receptors, Leukotriene | 2 | 2016 | 13 | 0.150 |
Why?
| | Algorithms | 4 | 2020 | 1839 | 0.150 |
Why?
| | Lung | 2 | 2007 | 4109 | 0.150 |
Why?
| | Drug Combinations | 2 | 2010 | 392 | 0.140 |
Why?
| | Chickenpox Vaccine | 1 | 1999 | 75 | 0.140 |
Why?
| | Histamine | 2 | 2011 | 53 | 0.140 |
Why?
| | Tosyl Compounds | 1 | 1998 | 16 | 0.140 |
Why?
| | Theophylline | 1 | 1998 | 41 | 0.140 |
Why?
| | STAT1 Transcription Factor | 2 | 2016 | 68 | 0.140 |
Why?
| | Bacterial Capsules | 2 | 2012 | 33 | 0.140 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2018 | 29 | 0.140 |
Why?
| | Lamiaceae | 1 | 1997 | 2 | 0.130 |
Why?
| | Artemisia | 1 | 1997 | 7 | 0.130 |
Why?
| | Plants, Medicinal | 1 | 1997 | 23 | 0.130 |
Why?
| | Meteorological Concepts | 1 | 1997 | 6 | 0.130 |
Why?
| | Drug Therapy, Combination | 3 | 2023 | 1048 | 0.130 |
Why?
| | Mycobacterium tuberculosis | 1 | 2001 | 337 | 0.130 |
Why?
| | Spores, Fungal | 1 | 1997 | 22 | 0.130 |
Why?
| | Primary Health Care | 1 | 2008 | 1734 | 0.130 |
Why?
| | Leukocyte Count | 3 | 2025 | 316 | 0.130 |
Why?
| | Lymphocytosis | 1 | 1997 | 11 | 0.130 |
Why?
| | Benzamides | 1 | 2018 | 224 | 0.130 |
Why?
| | Cohort Studies | 5 | 2025 | 5965 | 0.130 |
Why?
| | Air Microbiology | 1 | 1997 | 50 | 0.120 |
Why?
| | Common Variable Immunodeficiency | 1 | 1997 | 26 | 0.120 |
Why?
| | Pyrroles | 1 | 2018 | 218 | 0.120 |
Why?
| | Leukotrienes | 1 | 2016 | 27 | 0.120 |
Why?
| | Aging | 1 | 2007 | 1966 | 0.120 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 434 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 1997 | 100 | 0.120 |
Why?
| | Allergists | 1 | 2016 | 13 | 0.120 |
Why?
| | Interleukin-4 | 3 | 2013 | 206 | 0.120 |
Why?
| | Bacterial Toxins | 1 | 1997 | 110 | 0.120 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1169 | 0.120 |
Why?
| | Comorbidity | 4 | 2024 | 1660 | 0.120 |
Why?
| | Interleukins | 2 | 2013 | 248 | 0.120 |
Why?
| | Venoms | 1 | 2016 | 22 | 0.120 |
Why?
| | Administration, Oral | 2 | 2025 | 848 | 0.120 |
Why?
| | Leukoencephalopathy, Progressive Multifocal | 1 | 2016 | 38 | 0.120 |
Why?
| | Herpesvirus 3, Human | 1 | 1999 | 336 | 0.110 |
Why?
| | Canada | 1 | 2017 | 428 | 0.110 |
Why?
| | Insecta | 1 | 2016 | 74 | 0.110 |
Why?
| | Anti-Inflammatory Agents | 2 | 2012 | 475 | 0.110 |
Why?
| | Epinephrine | 1 | 2016 | 155 | 0.110 |
Why?
| | Leukocytes, Mononuclear | 1 | 1998 | 573 | 0.110 |
Why?
| | Drugs, Generic | 1 | 2015 | 27 | 0.110 |
Why?
| | Cardiac Tamponade | 1 | 1994 | 14 | 0.110 |
Why?
| | Bronchial Diseases | 1 | 1994 | 38 | 0.110 |
Why?
| | Papilloma | 1 | 1994 | 49 | 0.110 |
Why?
| | Tumor Virus Infections | 1 | 1994 | 49 | 0.110 |
Why?
| | Pentamidine | 1 | 1994 | 3 | 0.110 |
Why?
| | Gallium Radioisotopes | 1 | 1994 | 16 | 0.110 |
Why?
| | Phosphorylation | 2 | 2016 | 1733 | 0.100 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1994 | 34 | 0.100 |
Why?
| | Papillomaviridae | 1 | 1994 | 115 | 0.100 |
Why?
| | Basophils | 2 | 2013 | 52 | 0.100 |
Why?
| | Aerosols | 3 | 2001 | 186 | 0.100 |
Why?
| | Animals | 7 | 2017 | 38109 | 0.100 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2002 | 851 | 0.100 |
Why?
| | Bronchiectasis | 1 | 1994 | 112 | 0.100 |
Why?
| | Cluster Analysis | 2 | 2025 | 521 | 0.100 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1994 | 130 | 0.100 |
Why?
| | Pharmaceutical Preparations | 1 | 2015 | 170 | 0.100 |
Why?
| | Guidelines as Topic | 1 | 2015 | 268 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 2171 | 0.100 |
Why?
| | Evidence-Based Medicine | 1 | 2017 | 732 | 0.090 |
Why?
| | Drug Resistance | 1 | 2013 | 153 | 0.090 |
Why?
| | Salmonella Vaccines | 1 | 2012 | 2 | 0.090 |
Why?
| | Bacteriophage phi X 174 | 1 | 2012 | 5 | 0.090 |
Why?
| | Rabies Vaccines | 1 | 2012 | 3 | 0.090 |
Why?
| | Longitudinal Studies | 3 | 2025 | 2947 | 0.090 |
Why?
| | Olfaction Disorders | 1 | 2013 | 70 | 0.090 |
Why?
| | T-Lymphocytes | 2 | 2016 | 1982 | 0.090 |
Why?
| | Haemophilus Vaccines | 1 | 2012 | 29 | 0.090 |
Why?
| | Receptors, Histamine | 1 | 2011 | 2 | 0.090 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 28 | 0.090 |
Why?
| | Therapeutic Equivalency | 2 | 2025 | 31 | 0.090 |
Why?
| | Immunity, Humoral | 1 | 2012 | 120 | 0.090 |
Why?
| | History, 19th Century | 1 | 2011 | 62 | 0.090 |
Why?
| | Pneumococcal Vaccines | 1 | 2012 | 130 | 0.090 |
Why?
| | Salmeterol Xinafoate | 1 | 2010 | 20 | 0.080 |
Why?
| | Fluticasone | 1 | 2010 | 53 | 0.080 |
Why?
| | Retrospective Studies | 6 | 2024 | 17101 | 0.080 |
Why?
| | Health Surveys | 2 | 2012 | 518 | 0.080 |
Why?
| | Respiratory Mucosa | 1 | 2013 | 322 | 0.080 |
Why?
| | Papillomavirus Infections | 1 | 1994 | 345 | 0.080 |
Why?
| | History, 20th Century | 1 | 2011 | 325 | 0.080 |
Why?
| | Phenotype | 2 | 2017 | 3164 | 0.080 |
Why?
| | Cyclopropanes | 1 | 2010 | 83 | 0.080 |
Why?
| | Receptors, IgG | 1 | 2009 | 76 | 0.080 |
Why?
| | Medication Adherence | 1 | 2014 | 539 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2025 | 164 | 0.080 |
Why?
| | Congresses as Topic | 1 | 2011 | 221 | 0.070 |
Why?
| | Chemokine CCL26 | 1 | 2009 | 10 | 0.070 |
Why?
| | Chemokines, CC | 1 | 2009 | 32 | 0.070 |
Why?
| | Sulfides | 1 | 2010 | 92 | 0.070 |
Why?
| | Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 80 | 0.070 |
Why?
| | Bone Marrow | 2 | 2013 | 306 | 0.070 |
Why?
| | United States Food and Drug Administration | 1 | 2009 | 205 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2016 | 3608 | 0.070 |
Why?
| | Interleukin-13 | 1 | 2009 | 144 | 0.070 |
Why?
| | Clinical Competence | 1 | 2016 | 1244 | 0.070 |
Why?
| | Antibodies, Viral | 2 | 2025 | 672 | 0.070 |
Why?
| | Kartagener Syndrome | 1 | 2007 | 31 | 0.070 |
Why?
| | Adenosine | 1 | 2009 | 255 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2009 | 331 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 66 | 0.060 |
Why?
| | Recombinant Fusion Proteins | 1 | 2010 | 675 | 0.060 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2013 | 1129 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2018 | 6434 | 0.060 |
Why?
| | Health Status | 1 | 2012 | 836 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2009 | 479 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2009 | 557 | 0.060 |
Why?
| | Flushing | 1 | 2005 | 2 | 0.060 |
Why?
| | Administration, Topical | 1 | 2005 | 150 | 0.060 |
Why?
| | Penicillin G | 1 | 2004 | 7 | 0.060 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 24 | 0.050 |
Why?
| | Healthy Volunteers | 1 | 2025 | 215 | 0.050 |
Why?
| | New Zealand | 1 | 2025 | 54 | 0.050 |
Why?
| | Area Under Curve | 1 | 2025 | 331 | 0.050 |
Why?
| | Acute Disease | 1 | 2008 | 1031 | 0.050 |
Why?
| | Methylprednisolone Hemisuccinate | 1 | 2004 | 1 | 0.050 |
Why?
| | Mutation | 1 | 2016 | 4099 | 0.050 |
Why?
| | Clostridium botulinum | 1 | 2004 | 4 | 0.050 |
Why?
| | Anthrax Vaccines | 1 | 2004 | 7 | 0.050 |
Why?
| | Arenaviruses, New World | 1 | 2004 | 9 | 0.050 |
Why?
| | Dependovirus | 1 | 2025 | 79 | 0.050 |
Why?
| | Biomedical Research | 1 | 2011 | 710 | 0.050 |
Why?
| | Placebos | 2 | 2018 | 193 | 0.050 |
Why?
| | Infant | 1 | 2018 | 10039 | 0.050 |
Why?
| | Smallpox Vaccine | 1 | 2004 | 23 | 0.050 |
Why?
| | China | 1 | 2025 | 269 | 0.050 |
Why?
| | Diarrhea | 1 | 2005 | 192 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1167 | 0.050 |
Why?
| | Yersinia pestis | 1 | 2004 | 45 | 0.050 |
Why?
| | Bacterial Vaccines | 1 | 2004 | 63 | 0.050 |
Why?
| | Francisella tularensis | 1 | 2004 | 33 | 0.050 |
Why?
| | Headache | 1 | 2004 | 150 | 0.050 |
Why?
| | Insect Control | 1 | 2003 | 18 | 0.050 |
Why?
| | Food Contamination | 1 | 2003 | 56 | 0.050 |
Why?
| | Genetic Vectors | 1 | 2025 | 337 | 0.050 |
Why?
| | Child, Preschool | 1 | 2018 | 11799 | 0.050 |
Why?
| | Classification | 1 | 2003 | 43 | 0.050 |
Why?
| | Adjuvants, Immunologic | 1 | 2004 | 245 | 0.050 |
Why?
| | Disease Transmission, Infectious | 1 | 2003 | 69 | 0.050 |
Why?
| | Pain Measurement | 1 | 2005 | 555 | 0.050 |
Why?
| | Multimorbidity | 1 | 2023 | 63 | 0.050 |
Why?
| | Viral Vaccines | 1 | 2004 | 107 | 0.050 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2023 | 97 | 0.050 |
Why?
| | Disaster Planning | 1 | 2004 | 102 | 0.050 |
Why?
| | Antigens, Dermatophagoides | 1 | 2002 | 10 | 0.050 |
Why?
| | Genetic Therapy | 1 | 2025 | 313 | 0.050 |
Why?
| | Insurance Claim Review | 1 | 2022 | 83 | 0.050 |
Why?
| | Consumer Product Safety | 1 | 2002 | 32 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2002 | 35 | 0.050 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2002 | 11 | 0.040 |
Why?
| | Menstruation | 1 | 2002 | 42 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2025 | 1325 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2008 | 853 | 0.040 |
Why?
| | Drug Tolerance | 1 | 2002 | 100 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2025 | 1371 | 0.040 |
Why?
| | Time Factors | 2 | 2010 | 7183 | 0.040 |
Why?
| | Mycobacterium avium | 1 | 2001 | 21 | 0.040 |
Why?
| | Lung Neoplasms | 1 | 1994 | 2642 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2002 | 148 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2013 | 8279 | 0.040 |
Why?
| | Plant Extracts | 1 | 2002 | 187 | 0.040 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1540 | 0.040 |
Why?
| | Ultrasonic Therapy | 1 | 2000 | 16 | 0.040 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2007 | 923 | 0.040 |
Why?
| | Health Care Costs | 1 | 2023 | 427 | 0.040 |
Why?
| | Attention Deficit Disorder with Hyperactivity | 1 | 2004 | 428 | 0.040 |
Why?
| | Respiratory Mechanics | 1 | 2000 | 72 | 0.040 |
Why?
| | Neutrophils | 2 | 2017 | 1134 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2001 | 1048 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1486 | 0.040 |
Why?
| | Inflammation | 1 | 2010 | 2880 | 0.040 |
Why?
| | Phenylcarbamates | 1 | 1998 | 4 | 0.040 |
Why?
| | Leukotriene Antagonists | 1 | 1998 | 23 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 1998 | 2 | 0.040 |
Why?
| | Probenecid | 1 | 1998 | 8 | 0.030 |
Why?
| | Bronchoconstrictor Agents | 1 | 2018 | 14 | 0.030 |
Why?
| | S-Nitrosoglutathione | 1 | 2018 | 8 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 1999 | 370 | 0.030 |
Why?
| | Methacholine Chloride | 1 | 2018 | 50 | 0.030 |
Why?
| | Pregnancy | 1 | 2011 | 7191 | 0.030 |
Why?
| | Public Health | 1 | 2003 | 566 | 0.030 |
Why?
| | Pokeweed Mitogens | 1 | 1998 | 7 | 0.030 |
Why?
| | Phytohemagglutinins | 1 | 1998 | 29 | 0.030 |
Why?
| | Interleukin-4 Receptor alpha Subunit | 1 | 2018 | 9 | 0.030 |
Why?
| | Concanavalin A | 1 | 1998 | 71 | 0.030 |
Why?
| | Cells, Cultured | 2 | 2013 | 4155 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2018 | 85 | 0.030 |
Why?
| | Immunocompetence | 1 | 1998 | 47 | 0.030 |
Why?
| | Mitogens | 1 | 1998 | 55 | 0.030 |
Why?
| | Respiratory Function Tests | 2 | 2010 | 547 | 0.030 |
Why?
| | Equipment Design | 2 | 2015 | 530 | 0.030 |
Why?
| | Sodium Dodecyl Sulfate | 1 | 1997 | 26 | 0.030 |
Why?
| | Pollen | 1 | 1997 | 19 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2738 | 0.030 |
Why?
| | Cladosporium | 1 | 1997 | 1 | 0.030 |
Why?
| | Mitosporic Fungi | 1 | 1997 | 6 | 0.030 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 1997 | 51 | 0.030 |
Why?
| | Organophosphonates | 1 | 1998 | 97 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1997 | 166 | 0.030 |
Why?
| | Cross Reactions | 1 | 1997 | 130 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2010 | 5417 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 2007 | 1158 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2018 | 170 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 1997 | 122 | 0.030 |
Why?
| | Herpes Simplex | 1 | 1998 | 98 | 0.030 |
Why?
| | Immunization | 1 | 1999 | 374 | 0.030 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 1997 | 331 | 0.030 |
Why?
| | Immunoblotting | 1 | 1997 | 300 | 0.030 |
Why?
| | Drug Interactions | 1 | 1998 | 401 | 0.030 |
Why?
| | Superantigens | 1 | 1997 | 70 | 0.030 |
Why?
| | Enterotoxins | 1 | 1997 | 89 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1998 | 235 | 0.030 |
Why?
| | Prognosis | 1 | 2005 | 4293 | 0.030 |
Why?
| | JC Virus | 1 | 2016 | 23 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2009 | 6053 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2018 | 601 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2022 | 886 | 0.030 |
Why?
| | Workflow | 1 | 2017 | 185 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2023 | 5872 | 0.030 |
Why?
| | Biopsy | 2 | 2011 | 1077 | 0.030 |
Why?
| | Pharmacokinetics | 1 | 2015 | 32 | 0.030 |
Why?
| | Gene Expression Regulation | 2 | 2016 | 2609 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 1999 | 1126 | 0.030 |
Why?
| | IgA Deficiency | 1 | 1994 | 5 | 0.030 |
Why?
| | Pericarditis | 1 | 1994 | 11 | 0.030 |
Why?
| | Seasons | 1 | 1997 | 556 | 0.030 |
Why?
| | Indoles | 1 | 1998 | 501 | 0.030 |
Why?
| | Sulfonamides | 1 | 1998 | 581 | 0.030 |
Why?
| | Internationality | 1 | 2015 | 156 | 0.030 |
Why?
| | Radionuclide Imaging | 1 | 1994 | 113 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2004 | 1915 | 0.030 |
Why?
| | Self Report | 1 | 2018 | 873 | 0.030 |
Why?
| | Constriction, Pathologic | 1 | 1994 | 248 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 383 | 0.030 |
Why?
| | Receptors, Interleukin-5 | 1 | 2013 | 4 | 0.030 |
Why?
| | Suppressor of Cytokine Signaling Proteins | 1 | 2013 | 20 | 0.020 |
Why?
| | Risk Factors | 1 | 2008 | 10792 | 0.020 |
Why?
| | Viral Load | 1 | 2016 | 526 | 0.020 |
Why?
| | Hypersensitivity, Immediate | 1 | 2013 | 40 | 0.020 |
Why?
| | Arachidonic Acid | 1 | 2013 | 101 | 0.020 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 1998 | 1217 | 0.020 |
Why?
| | Flow Cytometry | 1 | 1997 | 1173 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 647 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2016 | 824 | 0.020 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2013 | 341 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 1997 | 460 | 0.020 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 1994 | 239 | 0.020 |
Why?
| | Histocytochemistry | 1 | 2011 | 79 | 0.020 |
Why?
| | Efficiency | 1 | 2012 | 104 | 0.020 |
Why?
| | Nasal Mucosa | 1 | 2011 | 112 | 0.020 |
Why?
| | Eosinophil Cationic Protein | 1 | 2010 | 9 | 0.020 |
Why?
| | Interleukin-5 Receptor alpha Subunit | 1 | 2010 | 6 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 1994 | 463 | 0.020 |
Why?
| | Prospective Studies | 1 | 2023 | 7997 | 0.020 |
Why?
| | Lymphopenia | 1 | 2010 | 65 | 0.020 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 418 | 0.020 |
Why?
| | Cell Count | 1 | 2010 | 321 | 0.020 |
Why?
| | Models, Biological | 1 | 1997 | 1822 | 0.020 |
Why?
| | Cats | 1 | 2009 | 228 | 0.020 |
Why?
| | Occupational Health | 1 | 2012 | 209 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 312 | 0.020 |
Why?
| | Sleep Wake Disorders | 1 | 2012 | 302 | 0.020 |
Why?
| | C-Reactive Protein | 1 | 2010 | 417 | 0.020 |
Why?
| | Cell Line, Tumor | 1 | 2016 | 3550 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 852 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2009 | 1311 | 0.020 |
Why?
| | Emotions | 1 | 2012 | 578 | 0.020 |
Why?
| | Exercise Test | 1 | 2009 | 634 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2010 | 780 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 2032 | 0.010 |
Why?
| | ROC Curve | 1 | 2005 | 615 | 0.010 |
Why?
| | Brain | 1 | 2016 | 2941 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2013 | 5997 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2430 | 0.010 |
Why?
| | Spectrophotometry | 1 | 2001 | 61 | 0.010 |
Why?
| | Rheology | 1 | 2001 | 94 | 0.010 |
Why?
| | Sodium Chloride | 1 | 2001 | 142 | 0.010 |
Why?
| | Particle Size | 1 | 2001 | 411 | 0.010 |
Why?
| | Cytosine | 1 | 1998 | 51 | 0.010 |
Why?
| | Organophosphorus Compounds | 1 | 1998 | 85 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18365 | 0.010 |
Why?
|
|
Katial's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|